Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 12/20 | 0.52 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24217683 | 0.87 | SSTR4 (0.45) | DGAT1SSTR4KDM4ESMN1; SMN2PPARA | |
| SCHEMBL10556663 | 0.86 | SSTR4 (0.52) | SSTR4KDM4ESMN1; SMN2NR4A2MAOB | |
| SCHEMBL5048630 | 0.84 | AR (0.47) | SSTR4KDM4ESMN1; SMN2PPARANR4A2 | |
| SCHEMBL21991543 | 0.84 | PPARA (0.57) | DGAT1CYP2C9KDM4ESMN1; SMN2PPARA | |
| SCHEMBL13948414 | 0.84 | CYP2C9 (0.61) | DGAT1CYP2C9SMN1; SMN2PPARAMAP4K4 | |
| SCHEMBL5724626 | 0.83 | PPARA (0.58) | DGAT1SSTR4CYP2C9PPARAMAP4K4 | |
| SCHEMBL21991531 | 0.83 | SSTR4 (0.53) | DGAT1SSTR4SMN1; SMN2MAOB | |
| SCHEMBL21991909 | 0.83 | PPARA (0.60) | DGAT1SMN1; SMN2PPARAMAOB | |
| SCHEMBL21991976 | 0.83 | PPARA (0.59) | DGAT1KDM4ESMN1; SMN2PPARA | |
| SCHEMBL11528571 | 0.82 | SSTR4 (0.47) | DGAT1SSTR4KDM4ESMN1; SMN2PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250049772-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-02-13 | — | — | US | disclosed |
| US-12005054-B2 | Piperidinyl-3-(aryloxy)propanamides and propanoates | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-11 | — | — | US | disclosed |
| CN-112236423-B | Piperidinyl-3- (aryloxy) propanamides and propionic acid esters | 武田药品工业株式会社 | 2024-02-06 | — | — | CN | disclosed |
| US-20230021834-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-26 | — | — | US | disclosed |
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-11045457-B2 | Piperidinyl-3-(aryloxy)propanamides and propanoates | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-06-29 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| CN-112236423-A | Piperidinyl-3- (aryloxy) propanamides and propionates | 武田药品工业株式会社 | 2021-01-15 | — | — | CN | disclosed |
| EP-3759094-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | Takeda Pharmaceutical Company Limited (JP) | 2021-01-06 | — | — | EP | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
| US-20200061041-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | DGAT1 525/4885SSTR4 2833/4885CYP2C9 1183/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | DGAT1 525/4885SSTR4 2833/4885CYP2C9 1183/4885 |
| US-11045457-B2 | Piperidinyl-3-(aryloxy)propanamides and propanoates | SSTR4, SSTR3, NPY4R | DGAT1 4831/4885SSTR4 1/4885CYP2C9 1229/4885 |
| US-12005054-B2 | Piperidinyl-3-(aryloxy)propanamides and propanoates | SSTR4, SSTR3, NPY4R | DGAT1 4831/4885SSTR4 1/4885CYP2C9 1229/4885 |
| US-20250049772-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | SSTR4, SSTR3, NPY4R | DGAT1 4831/4885SSTR4 1/4885CYP2C9 1229/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | DGAT1 525/4885SSTR4 2833/4885CYP2C9 1183/4885 |
| US-20200061041-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | SSTR4, SSTR3, NPY4R | DGAT1 4831/4885SSTR4 1/4885CYP2C9 1229/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | DGAT1 525/4885SSTR4 2833/4885CYP2C9 1183/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | DGAT1 525/4885SSTR4 2833/4885CYP2C9 1183/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | DGAT1 525/4885SSTR4 2833/4885CYP2C9 1183/4885 |
| US-20230021834-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | SSTR4, SSTR3, NPY4R | DGAT1 4831/4885SSTR4 1/4885CYP2C9 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.